^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    TMEM65 (Transmembrane Protein 65)

    i
    Other names: TMEM65, Transmembrane Protein 65
    Associations

    News

    Trials
    14d
    Modified Banxia Xiexin Decoction Promotes Mitochondrial Fission in Colon Cancer Cells by Inhibiting the CHD6-TMEM65 Axis. (PubMed, J Ethnopharmacol)
    The chemical constituents of mBXD mainly comprise flavonoids and alkaloids. These components markedly inhibit the growth of subcutaneous tumors in CT26 colon cancer-bearing mice and suppress the viability, invasiveness, and migratory capacity of HCT116 and CT26 cells. The underlying mechanism may involve the promotion of mitochondrial fission in cancer cells through inhibition of the CHD6-TMEM65 axis, ultimately leading to apoptosis. Nonetheless, the present study has certain limitations. The precise mechanisms by which mBXD induces mitochondrial fission and inhibits the CHD6-TMEM65 axis warrant further investigation in future research.
    Journal
    |
    CHD6 (Chromodomain Helicase DNA Binding Protein 6) • TMEM65 (Transmembrane Protein 65)
    5ms
    Integrating single-cell and bulk RNA sequencing data establishes a cuproptosis-related gene predictive signature in breast cancer. (PubMed, Discov Oncol)
    High-risk patients may benefit from intensified therapies or immunomodulatory strategies, while low-risk individuals could be considered for treatment de-escalation. In summary, our findings suggest that cuproptosis may play a regulatory role in BRCA progression and offer a novel, clinically actionable framework for prognostic stratification.
    Journal • BRCA Biomarker
    |
    TP53 (Tumor protein P53) • BRCA (Breast cancer early onset) • TMEM65 (Transmembrane Protein 65)
    |
    TP53 mutation
    6ms
    Integrative multi-omics analysis N4-acetylcytidine modification landscape and the role of TMEM65 in breast cancer. (PubMed, Int J Biol Macromol)
    Collectively, this study represents the first comprehensive exploration of ac4C modification in BC, introducing acRGBS as a novel biomarker that holds substantial prognostic and therapeutic implications. The identification of TMEM65 further highlights the translational potential of our findings in directing targeted therapeutic development, thus contributing significantly to the evolving landscape of precision medicine in BC.
    Journal
    |
    TMEM65 (Transmembrane Protein 65)
    8ms
    MYC/TET3-Regulated TMEM65 Activates OXPHOS-SERPINB3 Pathway to Promote Progression and Cisplatin Resistance in Triple-Negative Breast Cancer. (PubMed, Adv Sci (Weinh))
    Increased ROS induces the expression of hypoxia-inducible factor 1α (HIF1α), which in turn transcriptionally activates serpin family B member 3 (SERPINB3) to enhance TNBC stemness, thus leading to TNBC progression and cisplatin resistance. Collectively, these findings identify TMEM65 as a vital oncogene of TNBC, unveil its regulatory mechanisms, and shed light on its potential role in TNBC therapy.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • SERPINB3 (Serpin family B member 3) • TMEM65 (Transmembrane Protein 65)
    |
    cisplatin
    almost2years
    HBV integrations reshaping genomic structures promote hepatocellular carcinoma. (PubMed, Gut)
    HBV integrations extensively reshape genomic structures and promote hepatocarcinogenesis (graphical abstract), which may occur early in a patient's life.
    Journal
    |
    TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • TMEM65 (Transmembrane Protein 65)
    |
    TP53 mutation
    2years
    TMEM65 promotes gastric tumorigenesis by targeting YWHAZ to activate PI3K-Akt-mTOR pathway and is a therapeutic target. (PubMed, Oncogene)
    In conclusion, TMEM65 promotes gastric tumorigenesis by activating PI3K-Akt-mTOR signaling via cooperating with YWHAZ. TMEM65 overexpression may serve as an independent new biomarker and is a therapeutic target in GC.
    Journal
    |
    TMEM65 (Transmembrane Protein 65) • YWHAZ (Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Zeta)
    over2years
    Multi-omic Characterization and Molecular Profiling of NUT Carcinoma (AMP 2023)
    NRG1 fusion events are infrequently observed in ovarian, fallopian tube, and primary peritoneal carcinomas, and include a diversity of previously unknown partner genes. However, they may carry diagnostic significance in the context of borderline/low-grade serous tumors and have important therapeutic implications with the emergence of new targeted treatments.
    Tumor mutational burden • BRCA Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • PTEN (Phosphatase and tensin homolog) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • FGFR3 (Fibroblast growth factor receptor 3) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • ARID1A (AT-rich interaction domain 1A) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • NRG1 (Neuregulin 1) • KMT2D (Lysine Methyltransferase 2D) • CDK12 (Cyclin dependent kinase 12) • MUC16 (Mucin 16, Cell Surface Associated) • NOTCH2 (Notch 2) • CHEK2 (Checkpoint kinase 2) • ADAM9 (ADAM Metallopeptidase Domain 9) • EP300 (E1A binding protein p300) • RAD51D (RAD51 paralog D) • WRN (WRN RecQ Like Helicase) • IR (Insulin receptor) • FANCE (FA Complementation Group E) • JAG1 (Jagged Canonical Notch Ligand 1) • CXADR (CXADR Ig-Like Cell Adhesion Molecule) • FANCC (FA Complementation Group C) • TMEM65 (Transmembrane Protein 65) • TNFRSF12A (TNF Receptor Superfamily Member 12A)
    |
    NRG1 fusion • NRG1 fusion
    |
    MI Tumor Seek™
    almost3years
    Pan-Cancer Analysis of Prognostic and Immune Infiltrates for the TMEM65, Especially for the Breast Cancer. (PubMed, Evid Based Complement Alternat Med)
    Nomogram prediction model was also established for the breast tumors based on the TMEM65 level and other variables. Above all, the TMEM65 played important roles in predicting the prognosis of the cancers and correlated with the tumor immunity in the pan-cancer analysis.
    Journal • Tumor mutational burden • Pan tumor
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • TGFB1 (Transforming Growth Factor Beta 1) • TMEM65 (Transmembrane Protein 65)